ResearchSafe

Selank (Selank (TP-7))

Category: Cognitive & Nootropic. Status: Research compound.

A synthetic analog of tuftsin with Pro-Gly-Pro for stability. Developed at the Russian Academy of Sciences with anxiolytic and nootropic properties without sedation or addiction.

How it works

Modulates GABA-A allosteric sites, increases BDNF, stabilizes enkephalin degradation, and influences serotonin metabolism. Enhances IL-6 and Th1/Th2 balance.

Key facts

  • Molecular weight: 751.9 Da
  • Half-life: 3-5 min (IV) / 15-30 min (intranasal)
  • Bioavailability: Moderate (intranasal)
  • Storage: Solution: 2-8°C. Protected from light.

Dosing overview

  • Typical dose: 250-750 mcg per spray dose
  • Frequency: 2-3x daily
  • Duration: 2-4 week courses
  • Route: Intranasal spray

Protocol notes

  • Delivered intranasally, split across 2-3 doses through the day.
  • Run in 2-4 week courses; commonly stacked with Semax for a calm-but-focused nootropic combo.

Reported benefits

  • Anxiolytic without sedation
  • Improved memory/learning
  • Cognitive flexibility
  • Immune modulation
  • BDNF upregulation
  • No addiction

Possible side effects

  • Nasal irritation
  • Mild fatigue (initial)
  • Headache (rare)

Research

  • Selank anxiolytic effects vs benzodiazepines (2021): Equivalent anxiolysis to diazepam in GAD without cognitive impairment or dependence over 8 weeks.
  • BDNF modulation by selank (2020): Increased hippocampal BDNF by 60% and improved spatial memory by 35% in aged models.

Compare Selank

Community discussions about Selank

Research and educational reference only. Not medical advice.